| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcohol Drinking | 42 | 2025 | 283 | 9.680 |
Why?
|
| Smoking Cessation | 28 | 2025 | 269 | 8.310 |
Why?
|
| Alcoholism | 23 | 2025 | 188 | 6.910 |
Why?
|
| Ethanol | 37 | 2025 | 273 | 6.690 |
Why?
|
| Smoking | 27 | 2025 | 647 | 6.180 |
Why?
|
| Electronic Nicotine Delivery Systems | 10 | 2025 | 72 | 5.210 |
Why?
|
| Naltrexone | 16 | 2019 | 139 | 4.330 |
Why?
|
| Cues | 11 | 2025 | 186 | 3.990 |
Why?
|
| Vaping | 6 | 2025 | 43 | 3.430 |
Why?
|
| Reward | 9 | 2025 | 209 | 2.980 |
Why?
|
| Narcotic Antagonists | 12 | 2019 | 170 | 2.910 |
Why?
|
| Alcoholic Intoxication | 7 | 2025 | 37 | 2.330 |
Why?
|
| Tobacco Products | 6 | 2025 | 77 | 2.240 |
Why?
|
| Smokers | 6 | 2025 | 54 | 2.100 |
Why?
|
| Adult | 89 | 2025 | 27849 | 2.010 |
Why?
|
| Young Adult | 50 | 2025 | 6922 | 1.800 |
Why?
|
| Tobacco Use Disorder | 7 | 2019 | 121 | 1.770 |
Why?
|
| Nicotine | 7 | 2025 | 208 | 1.720 |
Why?
|
| Alcoholic Beverages | 4 | 2021 | 12 | 1.710 |
Why?
|
| Hydrocortisone | 14 | 2025 | 294 | 1.650 |
Why?
|
| Male | 88 | 2025 | 44353 | 1.570 |
Why?
|
| Central Nervous System Depressants | 9 | 2021 | 45 | 1.520 |
Why?
|
| Craving | 5 | 2019 | 24 | 1.450 |
Why?
|
| Female | 86 | 2025 | 48540 | 1.450 |
Why?
|
| Double-Blind Method | 25 | 2019 | 1727 | 1.390 |
Why?
|
| Motivation | 6 | 2021 | 310 | 1.380 |
Why?
|
| Humans | 107 | 2025 | 93130 | 1.250 |
Why?
|
| Tobacco Smoking | 2 | 2021 | 31 | 1.230 |
Why?
|
| Affect | 9 | 2025 | 397 | 1.220 |
Why?
|
| Psychomotor Performance | 8 | 2018 | 497 | 1.190 |
Why?
|
| Mobile Applications | 2 | 2021 | 78 | 1.170 |
Why?
|
| Alcohol-Related Disorders | 3 | 2021 | 18 | 1.150 |
Why?
|
| Surveys and Questionnaires | 15 | 2025 | 2787 | 1.090 |
Why?
|
| Tobacco Use Cessation | 2 | 2017 | 10 | 1.020 |
Why?
|
| Behavior, Addictive | 5 | 2019 | 137 | 0.950 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2018 | 26 | 0.950 |
Why?
|
| Smoking Reduction | 1 | 2025 | 4 | 0.900 |
Why?
|
| Hypnotics and Sedatives | 3 | 2017 | 137 | 0.880 |
Why?
|
| Carcinogens | 1 | 2025 | 101 | 0.870 |
Why?
|
| Smartphone | 3 | 2025 | 52 | 0.860 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 47 | 0.860 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 250 | 0.850 |
Why?
|
| Behavior Therapy | 2 | 2021 | 92 | 0.780 |
Why?
|
| Courage | 1 | 2023 | 8 | 0.770 |
Why?
|
| Psychometrics | 6 | 2018 | 336 | 0.770 |
Why?
|
| Depression | 2 | 2025 | 540 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2025 | 1908 | 0.710 |
Why?
|
| Telemedicine | 1 | 2025 | 223 | 0.690 |
Why?
|
| Binge Drinking | 3 | 2022 | 15 | 0.680 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 290 | 0.680 |
Why?
|
| Middle Aged | 34 | 2025 | 27535 | 0.680 |
Why?
|
| Self Efficacy | 2 | 2019 | 58 | 0.670 |
Why?
|
| Crisis Intervention | 1 | 2021 | 13 | 0.670 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1160 | 0.660 |
Why?
|
| Patient Selection | 2 | 2017 | 688 | 0.640 |
Why?
|
| Biomarkers | 3 | 2025 | 1905 | 0.630 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 500 | 0.620 |
Why?
|
| Sex Factors | 9 | 2018 | 1102 | 0.620 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 3814 | 0.620 |
Why?
|
| Self Report | 5 | 2020 | 328 | 0.610 |
Why?
|
| Saccades | 3 | 2013 | 75 | 0.610 |
Why?
|
| Genotype | 3 | 2019 | 1866 | 0.600 |
Why?
|
| Smoking Prevention | 4 | 2022 | 46 | 0.580 |
Why?
|
| Receptors, Opioid | 1 | 2019 | 23 | 0.580 |
Why?
|
| Glycerol | 1 | 2019 | 33 | 0.570 |
Why?
|
| Vegetables | 1 | 2019 | 50 | 0.570 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 37 | 0.560 |
Why?
|
| Central Nervous System Stimulants | 2 | 2019 | 233 | 0.560 |
Why?
|
| Research Design | 2 | 2012 | 620 | 0.550 |
Why?
|
| Nicotinic Agonists | 3 | 2022 | 73 | 0.550 |
Why?
|
| Treatment Outcome | 13 | 2019 | 9070 | 0.540 |
Why?
|
| Tobacco Use | 1 | 2018 | 29 | 0.530 |
Why?
|
| Feasibility Studies | 5 | 2025 | 753 | 0.530 |
Why?
|
| Social Behavior | 4 | 2018 | 307 | 0.530 |
Why?
|
| Stimulation, Chemical | 1 | 2017 | 54 | 0.520 |
Why?
|
| Pilot Projects | 7 | 2022 | 913 | 0.520 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2012 | 53 | 0.510 |
Why?
|
| Professional Practice | 1 | 2017 | 43 | 0.500 |
Why?
|
| Referral and Consultation | 2 | 2024 | 373 | 0.500 |
Why?
|
| Pituitary-Adrenal System | 3 | 2012 | 64 | 0.500 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 17 | 0.500 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2012 | 78 | 0.500 |
Why?
|
| Bisexuality | 1 | 2017 | 36 | 0.500 |
Why?
|
| Transsexualism | 1 | 2017 | 24 | 0.490 |
Why?
|
| Health Personnel | 1 | 2019 | 234 | 0.490 |
Why?
|
| Sex Characteristics | 4 | 2012 | 334 | 0.490 |
Why?
|
| Research Subjects | 1 | 2017 | 73 | 0.490 |
Why?
|
| Health Promotion | 3 | 2014 | 170 | 0.480 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 13 | 0.460 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 20 | 0.450 |
Why?
|
| Weight Gain | 2 | 2012 | 127 | 0.440 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 826 | 0.440 |
Why?
|
| Luteal Phase | 1 | 2014 | 14 | 0.440 |
Why?
|
| Follicular Phase | 1 | 2014 | 11 | 0.430 |
Why?
|
| Drinking Behavior | 1 | 2014 | 13 | 0.430 |
Why?
|
| Breath Tests | 5 | 2025 | 58 | 0.430 |
Why?
|
| Prolactin | 1 | 2014 | 89 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 557 | 0.430 |
Why?
|
| Saliva | 7 | 2015 | 124 | 0.420 |
Why?
|
| Stress, Psychological | 5 | 2013 | 343 | 0.400 |
Why?
|
| Biosensing Techniques | 2 | 2025 | 81 | 0.400 |
Why?
|
| Psychotherapy, Group | 2 | 2013 | 37 | 0.400 |
Why?
|
| Community Health Services | 1 | 2014 | 79 | 0.390 |
Why?
|
| Homosexuality, Male | 1 | 2017 | 332 | 0.390 |
Why?
|
| Eye Movements | 2 | 2012 | 119 | 0.390 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2016 | 286 | 0.390 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 49 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2017 | 432 | 0.370 |
Why?
|
| Sexual Partners | 1 | 2013 | 103 | 0.360 |
Why?
|
| Medical Records | 1 | 2012 | 121 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 618 | 0.350 |
Why?
|
| Adolescent | 13 | 2025 | 9550 | 0.340 |
Why?
|
| Internet | 2 | 2019 | 345 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 916 | 0.330 |
Why?
|
| Mental Recall | 1 | 2012 | 172 | 0.330 |
Why?
|
| Eligibility Determination | 1 | 2011 | 39 | 0.330 |
Why?
|
| Cotinine | 2 | 2025 | 15 | 0.320 |
Why?
|
| Poverty | 2 | 2023 | 192 | 0.320 |
Why?
|
| Sexual Behavior | 1 | 2013 | 328 | 0.320 |
Why?
|
| Physicians | 1 | 2017 | 668 | 0.310 |
Why?
|
| Pursuit, Smooth | 2 | 2013 | 31 | 0.300 |
Why?
|
| Basal Ganglia | 1 | 2009 | 46 | 0.300 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2009 | 6 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2013 | 290 | 0.290 |
Why?
|
| Chicago | 5 | 2019 | 1452 | 0.290 |
Why?
|
| Amygdala | 3 | 2016 | 86 | 0.290 |
Why?
|
| Social Environment | 2 | 2007 | 194 | 0.290 |
Why?
|
| Administration, Cutaneous | 2 | 2022 | 61 | 0.280 |
Why?
|
| Substance-Related Disorders | 4 | 2020 | 440 | 0.280 |
Why?
|
| Time Factors | 6 | 2025 | 5380 | 0.270 |
Why?
|
| Analysis of Variance | 7 | 2016 | 883 | 0.270 |
Why?
|
| Preventive Health Services | 1 | 2008 | 37 | 0.260 |
Why?
|
| Aged | 11 | 2025 | 20395 | 0.250 |
Why?
|
| Oxytocin | 2 | 2018 | 73 | 0.250 |
Why?
|
| Anger | 3 | 2016 | 80 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2008 | 214 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1447 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 1071 | 0.240 |
Why?
|
| Residence Characteristics | 1 | 2008 | 212 | 0.240 |
Why?
|
| Blood Alcohol Content | 2 | 2022 | 7 | 0.230 |
Why?
|
| Cultural Characteristics | 2 | 2019 | 19 | 0.230 |
Why?
|
| Nitrosamines | 1 | 2025 | 9 | 0.230 |
Why?
|
| Family Health | 2 | 2018 | 154 | 0.220 |
Why?
|
| Wearable Electronic Devices | 1 | 2025 | 36 | 0.220 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2004 | 25 | 0.220 |
Why?
|
| Cohort Studies | 3 | 2019 | 3044 | 0.210 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2024 | 18 | 0.210 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2024 | 24 | 0.200 |
Why?
|
| Patient Dropouts | 1 | 2004 | 31 | 0.200 |
Why?
|
| Risk Factors | 5 | 2022 | 5900 | 0.200 |
Why?
|
| Photic Stimulation | 4 | 2015 | 506 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2019 | 4546 | 0.200 |
Why?
|
| United States | 5 | 2024 | 7581 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2025 | 90 | 0.200 |
Why?
|
| Prevalence | 4 | 2020 | 1318 | 0.190 |
Why?
|
| Life Change Events | 1 | 2003 | 45 | 0.190 |
Why?
|
| Counseling | 3 | 2015 | 164 | 0.190 |
Why?
|
| Melatonin | 1 | 2022 | 46 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 346 | 0.180 |
Why?
|
| Health Behavior | 2 | 2017 | 182 | 0.170 |
Why?
|
| Personality | 1 | 2003 | 140 | 0.170 |
Why?
|
| Radiology | 1 | 2024 | 199 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 100 | 0.170 |
Why?
|
| Tablets | 1 | 2022 | 127 | 0.170 |
Why?
|
| Motivational Interviewing | 1 | 2021 | 21 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2013 | 312 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2705 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 90 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2020 | 28 | 0.160 |
Why?
|
| Marketing | 1 | 2019 | 23 | 0.150 |
Why?
|
| Women | 1 | 2019 | 26 | 0.150 |
Why?
|
| Environment | 1 | 2021 | 230 | 0.150 |
Why?
|
| Exhalation | 1 | 2019 | 13 | 0.150 |
Why?
|
| Aerosols | 1 | 2019 | 44 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 1910 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2484 | 0.140 |
Why?
|
| Heart Rate | 2 | 2018 | 505 | 0.140 |
Why?
|
| Phenotype | 2 | 2015 | 2545 | 0.130 |
Why?
|
| Heterozygote | 1 | 2018 | 381 | 0.130 |
Why?
|
| Mass Screening | 3 | 2024 | 706 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2009 | 123 | 0.130 |
Why?
|
| China | 2 | 2015 | 264 | 0.130 |
Why?
|
| Illinois | 1 | 2019 | 515 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2012 | 655 | 0.120 |
Why?
|
| Culture | 1 | 2017 | 54 | 0.120 |
Why?
|
| Disease Progression | 1 | 2021 | 1528 | 0.120 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2015 | 11 | 0.110 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 221 | 0.110 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2015 | 42 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2017 | 346 | 0.110 |
Why?
|
| Alcohol Abstinence | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2019 | 451 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 627 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2013 | 359 | 0.100 |
Why?
|
| Ecological Momentary Assessment | 2 | 2025 | 39 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2013 | 18 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2019 | 10128 | 0.100 |
Why?
|
| Color Vision Defects | 1 | 2012 | 22 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 389 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 480 | 0.090 |
Why?
|
| Aggression | 1 | 2016 | 330 | 0.090 |
Why?
|
| Contrast Sensitivity | 1 | 2012 | 72 | 0.090 |
Why?
|
| Genetics, Behavioral | 1 | 2012 | 22 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 3450 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2013 | 179 | 0.090 |
Why?
|
| Amphetamine | 1 | 2012 | 101 | 0.090 |
Why?
|
| Quinoxalines | 1 | 2012 | 51 | 0.090 |
Why?
|
| Visual Pathways | 1 | 2012 | 151 | 0.090 |
Why?
|
| Emotions | 2 | 2016 | 368 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 64 | 0.090 |
Why?
|
| Community Health Centers | 1 | 2013 | 119 | 0.090 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 150 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 2363 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2465 | 0.080 |
Why?
|
| Fear | 1 | 2010 | 87 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2009 | 236 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1898 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 301 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 205 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 72 | 0.070 |
Why?
|
| Body Weight | 1 | 2010 | 449 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 71 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 129 | 0.070 |
Why?
|
| Patients | 1 | 2010 | 103 | 0.070 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 108 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1719 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 456 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 373 | 0.070 |
Why?
|
| Arousal | 2 | 2005 | 171 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2008 | 88 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2007 | 17 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 99 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2018 | 140 | 0.060 |
Why?
|
| Psychopharmacology | 1 | 2006 | 26 | 0.060 |
Why?
|
| Temperance | 2 | 2003 | 6 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 354 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 224 | 0.060 |
Why?
|
| Behavior | 1 | 2006 | 85 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2006 | 164 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 3168 | 0.050 |
Why?
|
| Liver | 1 | 2009 | 1205 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2024 | 23 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2025 | 158 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 7039 | 0.050 |
Why?
|
| Anxiety | 2 | 2020 | 336 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 288 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2003 | 99 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2004 | 159 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 46 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 61 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 272 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 984 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2003 | 245 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 218 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2002 | 235 | 0.040 |
Why?
|
| Logistic Models | 1 | 2004 | 1240 | 0.040 |
Why?
|
| Alcohol Deterrents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2007 | 808 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 800 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 285 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 170 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 504 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2020 | 219 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 448 | 0.030 |
Why?
|
| Oxytocics | 1 | 2018 | 25 | 0.030 |
Why?
|
| Universities | 1 | 2019 | 150 | 0.030 |
Why?
|
| Reference Values | 2 | 2012 | 603 | 0.030 |
Why?
|
| Hypertension | 1 | 2003 | 748 | 0.030 |
Why?
|
| Algorithms | 1 | 2025 | 1948 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1098 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 148 | 0.020 |
Why?
|
| Psychophysics | 1 | 2012 | 72 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1003 | 0.020 |
Why?
|
| Varenicline | 1 | 2012 | 16 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 93 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 887 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2013 | 324 | 0.020 |
Why?
|
| Body Image | 1 | 2010 | 84 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1269 | 0.020 |
Why?
|
| Income | 1 | 2009 | 86 | 0.020 |
Why?
|
| Individuality | 1 | 2010 | 114 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 1004 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 226 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2010 | 712 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 341 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1703 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 43 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 2003 | 34 | 0.010 |
Why?
|
| Hand Strength | 1 | 2003 | 57 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 118 | 0.010 |
Why?
|
| Speech | 1 | 2003 | 90 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1054 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 573 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 541 | 0.010 |
Why?
|